KISQALI FEMARA CO-PACK (COPACKAGED) Drug Patent Profile
✉ Email this page to a colleague
When do Kisqali Femara Co-pack (copackaged) patents expire, and when can generic versions of Kisqali Femara Co-pack (copackaged) launch?
Kisqali Femara Co-pack (copackaged) is a drug marketed by Novartis and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eighty-four patent family members in fifty-three countries.
The generic ingredient in KISQALI FEMARA CO-PACK (COPACKAGED) is letrozole; ribociclib succinate. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the letrozole; ribociclib succinate profile page.
DrugPatentWatch® Generic Entry Outlook for Kisqali Femara Co-pack (copackaged)
Kisqali Femara Co-pack (copackaged) was eligible for patent challenges on March 13, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 14, 2036. This may change due to patent challenges or generic licensing.
There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for KISQALI FEMARA CO-PACK (COPACKAGED)
International Patents: | 184 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KISQALI FEMARA CO-PACK (COPACKAGED) |
DailyMed Link: | KISQALI FEMARA CO-PACK (COPACKAGED) at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for KISQALI FEMARA CO-PACK (COPACKAGED)
Generic Entry Date for KISQALI FEMARA CO-PACK (COPACKAGED)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for KISQALI FEMARA CO-PACK (COPACKAGED)
Paragraph IV (Patent) Challenges for KISQALI FEMARA CO-PACK (COPACKAGED)
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
KISQALI FEMARA CO-PACK (COPACKAGED) | Tablets | letrozole; ribociclib succinate | 200 mg and 2.5 mg | 209935 | 4 | 2021-03-15 |
US Patents and Regulatory Information for KISQALI FEMARA CO-PACK (COPACKAGED)
KISQALI FEMARA CO-PACK (COPACKAGED) is protected by eleven US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of KISQALI FEMARA CO-PACK (COPACKAGED) is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting KISQALI FEMARA CO-PACK (COPACKAGED)
Ribociclib tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyrrolopyrimidine compounds and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyrrolopyrimidine compounds and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyrrolopyrimidine compounds and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyrrolopyrimidine compounds and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Pyrrolopyrimidine compounds and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo- [2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyrrolopyrimidine compounds and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Pyrrolopyrimidine compounds and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo- [2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo- [2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
FDA Regulatory Exclusivity protecting KISQALI FEMARA CO-PACK (COPACKAGED)
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
International Patents for KISQALI FEMARA CO-PACK (COPACKAGED)
When does loss-of-exclusivity occur for KISQALI FEMARA CO-PACK (COPACKAGED)?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 4257
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 16248017
Estimated Expiration: ⤷ Sign Up
Patent: 19201929
Estimated Expiration: ⤷ Sign Up
Patent: 20250190
Estimated Expiration: ⤷ Sign Up
Patent: 22215155
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017021283
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 82425
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 17002593
Estimated Expiration: ⤷ Sign Up
China
Patent: 7530292
Estimated Expiration: ⤷ Sign Up
Patent: 5554257
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 17010510
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0230053
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 83058
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 17075052
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1792290
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 83058
Estimated Expiration: ⤷ Sign Up
Patent: 97530
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 83058
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 61213
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 18514523
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 17013350
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 180035
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 017501820
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 83058
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 83058
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201708084P
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 83058
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 170137101
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 38261
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 1642864
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 17000422
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering KISQALI FEMARA CO-PACK (COPACKAGED) around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20200136493 | 7-시클로펜틸-2- 및 그의 제조 방법 (7--2-5--1---2--7-[23-]-6- SALTS OF 7-CYCLOPENTYL-2-5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO-7H-PYRROLO[23-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF) | ⤷ Sign Up |
Serbia | 53574 | PIROLOPIRIMIDINSKA JEDINJENJA KAO INHIBITORI CDK (CIKLIN ZAVISNE KINAZE) (PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS) | ⤷ Sign Up |
Poland | 3283058 | ⤷ Sign Up | |
Taiwan | 201642864 | RIBOCICLIB tablet | ⤷ Sign Up |
Japan | 2019038809 | 7−シクロペンチル−2−(5−ピペラジン−1−イル−ピリジン−2−イルアミノ)−7H−ピロロ[2,3−D]ピリミジン−6−カルボン酸ジメチルアミドの塩およびその製造方法 (SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF) | ⤷ Sign Up |
France | 17C1059 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for KISQALI FEMARA CO-PACK (COPACKAGED)
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2331547 | C20170039 00245 | Estonia | ⤷ Sign Up | PRODUCT NAME: RIBOTSIKLIIB;REG NO/DATE: EU/1/17/1221 24.08.2017 |
2331547 | 66/2017 | Austria | ⤷ Sign Up | PRODUCT NAME: RIBOCICLIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1221 (MITTEILUNG) 20170824 |
2331547 | 664 | Finland | ⤷ Sign Up | |
2331547 | C02331547/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: RIBOCICLIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66377 24.10.2017 |
2331547 | CR 2017 00060 | Denmark | ⤷ Sign Up | PRODUCT NAME: RIBOCICLIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/17/1221 20170824 |
2331547 | SPC/GB17/074 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: RIBOCICLIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1221/001-012 20170824; UK PLGB 00101/1100 20170824 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |